Discover a detailed exploration of the Lumasiran Market by Data Bridge Market Research, thoughtfully presented with visual finesse to ensure seamless data absorption. Crucial insights are illuminated through vivid graphs, charts, and figures, empowering astute decision-making.
The Lumasiran market research report stands out as an exemplary, practical, and commendable analysis that reflects an unwavering dedication and understanding of business requirements. Sourcing information from reputable outlets such as company annual reports, websites, and journals, the data within the Lumasiran report undergoes thorough validation by market experts. Utilizing well-established statistical and coherent models, the market data is not only analyzed but also forecasted accurately. The report's timeliness is evident in its cutting-edge market insights, providing a clear perspective on the marketplace.
This comprehensive Lumasiran market research report encompasses six vital parameters: market analysis, market definition, market segmentation, key market developments, competitive analysis, and research methodology. Competitive analysis takes center stage, covering strategic profiling of key market players, an in-depth analysis of their core competencies, and the creation of a competitive landscape for the market. The report delves into key players, significant collaborations, mergers and acquisitions, as well as trending innovations and business policies shaping the Lumasiran market.
Global lumasiran market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 7.30% in the above mentioned forecast period.
Get Sample Research Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-lumasiran-market
Market Definition:
Lumasiran, also known as Oxlumo is a HAO1-directed small interfering ribonucleic acid (siRNA). It is used to treat primary hyperoxaluria type1 (PH1) by lowering urinary oxalate levels in pediatric and adult patients. Primary hyperoxaluria type1 is a rare genetic metabolic disorder in which level of oxalate increases in the urine and further results in the kidney failure or kidney stones.
Market Growth Drivers:
Rise in the prevalence of primary hyperoxaluria, inevitable inheritance of the disease, advancement of therapies for treatment of rare diseases, and increase in the awareness towards genetic diseases coupled with genetic counselling are the factors that will expand the global lumasiran market.
Rise in research and development activities and ongoing clinical trials are expected to provide beneficial opportunities for the global lumasiran market in the forecast period of 2021-2028.
Lumasiran shows side effects such as abdominal pain, breathing difficulties, and injection site reaction (redness, swelling, pain, and itching). These side effects and lack of medical publications are the factors that will restraint the market growth. High cost of medication, focus of developing therapies on the novel approaches to treat the rare diseases and storage condition are the factors that will challenge the global lumasiran market in the forecast period mentioned above.
Notably, the report emphasizes the engagement of essential entities, including:
Alnylam Pharmaceuticals, Inc. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America
Key highlights of the report: